Dobrovolskaia MA - Search Results

1

Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines.

Newton HS, Dobrovolskaia MA. Newton HS, et al. Among authors: dobrovolskaia ma. Adv Drug Deliv Rev. 2022 Jun;185:114281. doi: 10.1016/j.addr.2022.114281. Epub 2022 Apr 9. Adv Drug Deliv Rev. 2022. PMID: 35405297 Free PMC article. Review.

2

Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Aggarwal P, et al. Among authors: dobrovolskaia ma. Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37. doi: 10.1016/j.addr.2009.03.009. Epub 2009 Apr 17. Adv Drug Deliv Rev. 2009. PMID: 19376175 Free PMC article. Review.

3

Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

Dobrovolskaia MA, McNeil SE. Dobrovolskaia MA, et al. J Control Release. 2013 Dec 10;172(2):456-66. doi: 10.1016/j.jconrel.2013.05.025. Epub 2013 Jun 3. J Control Release. 2013. PMID: 23742883 Free PMC article. Review.

4

Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.

Dobrovolskaia MA, McNeil SE. Dobrovolskaia MA, et al. Expert Opin Drug Deliv. 2015 Jul;12(7):1163-75. doi: 10.1517/17425247.2015.1042857. Epub 2015 May 20. Expert Opin Drug Deliv. 2015. PMID: 25994601 Review.

5

Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Dobrovolskaia MA. Dobrovolskaia MA. J Control Release. 2015 Dec 28;220(Pt B):571-83. doi: 10.1016/j.jconrel.2015.08.056. Epub 2015 Sep 5. J Control Release. 2015. PMID: 26348388 Free PMC article. Review.

6

Current understanding of interactions between nanoparticles and the immune system.

Dobrovolskaia MA, Shurin M, Shvedova AA. Dobrovolskaia MA, et al. Toxicol Appl Pharmacol. 2016 May 15;299:78-89. doi: 10.1016/j.taap.2015.12.022. Epub 2015 Dec 29. Toxicol Appl Pharmacol. 2016. PMID: 26739622 Free PMC article. Review.

7

Analysis of Nanoparticle-Adjuvant Properties In Vivo.

Neun BW, Dobrovolskaia MA. Neun BW, et al. Among authors: dobrovolskaia ma. Methods Mol Biol. 2018;1682:189-195. doi: 10.1007/978-1-4939-7352-1_16. Methods Mol Biol. 2018. PMID: 29039103

8

Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics.

Hong E, Dobrovolskaia MA. Hong E, et al. Among authors: dobrovolskaia ma. Adv Drug Deliv Rev. 2019 Feb 15;141:3-22. doi: 10.1016/j.addr.2018.01.005. Epub 2018 Jan 12. Adv Drug Deliv Rev. 2019. PMID: 29339144 Review.

9

Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations.

Zamboni WC, Szebeni J, Kozlov SV, Lucas AT, Piscitelli JA, Dobrovolskaia MA. Zamboni WC, et al. Among authors: dobrovolskaia ma. Adv Drug Deliv Rev. 2018 Nov-Dec;136-137:82-96. doi: 10.1016/j.addr.2018.09.012. Epub 2018 Sep 29. Adv Drug Deliv Rev. 2018. PMID: 30273617 Review.

10

Roadmap and strategy for overcoming infusion reactions to nanomedicines.

Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA. Szebeni J, et al. Among authors: dobrovolskaia ma. Nat Nanotechnol. 2018 Dec;13(12):1100-1108. doi: 10.1038/s41565-018-0273-1. Epub 2018 Oct 22. Nat Nanotechnol. 2018. PMID: 30348955 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page